	Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 06275-004003	Application No.
Information Disclosure Statement by Applicant		Applicant Bäckström et al.		
I	(Modified) Patent and Trademark Office Information Disclosure Statement by Applicant (Use several sheets if necessary)	Filing Date	Group Art Unit	
	(37 CFR §1.98(b))			

			U.S. Patent	Documents			
Examiner (Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appro priate
XX	AA	2,992,645	07/18/61	Fowler			priorio
	AB	3,014,844	12/26/2001	Thiel			
	AC	3,671,625	06/1972	Altounyan			
	AD	3,911,138	10/07/1975	Clark	424	352	
	AE .	4,232,002	11/1980	Nogrady			
	AF	4,462,983	07/1984	Azria			
	AG	4,524,769	06/25/1985	Wetterlin	128	203.15	
	AH	4,534,345	08/13/1985	Wetterlin	128	203.15	
	AI	4,537,772	08/1985	Alexander			
$\bigcap_{i} V_i$	AJ	4,548,922	10/22/1985	Carey et al.	-514	4	
AL	AK	4,613,500	09/23/1986	Suzuki et al.	424	85.4	
	AL	4,668,218	05/26/2987	Virtanen	604	58	
	AM	4,690,952	09/01/1987	Kagatani et al.	514	11	
	AN	4,731,360	03/1988	Alexander			
	AO	4,746,508	05/24/1988	Carey et al.	424	88	
	AP	4,788,221	11/29/1988	Kagatani et al.	514	12	
	AQ	4,847,298	04/11/1989	Alexander			
	AR	4,895,719	01/23/1990	Radhakrishnan			
	AS	4,900,730	02/13/1990	Miyauchi	514	12-	
	AT	4,907,583	03/13/1990	Wetterlin et al.	-128	203.15	
	AU	4,914,084	04/03/1990	Ecanow	514	006	
	AV	4,920,061	04/24/1990	Poynton	436	-526-	
	AW	4,926,852	05/22/90	Zoltan et al.	128	200.23	
(Y)	AX	4,959,358	09/28/1998	Carey et al.	514	171	
SIL	AY	4,963,367	10/16/1990	Ecanow			

Examiner Signature	Date Considered
- WICK WINGEN	1-1-00
EXAMINER: Initials citation considered. Draw line through citation if	not in conformance and not considered. Include copy of this form with
next communication to applicant.	not in comorniance and not considered, include copy of this form with

	Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 06275-004003	Application No.	
*		Applicant Bäckström et al.			
	Modified) Patent and T Information Disclosure Stateme by Applicant (Use several sheets if necessary)	neets if necessary)	Filing Date	Group Art Unit	
I	(37 CFR §1.98(b))				

	Desig. Document Publication Date Patentee Class Subclass Filing Date If Appro Patentee AZ 4,994,439 02/19/1991 Longnecker AAA 5,006,343 04/09/1991 Benson ABB 5,011,678 04/30/1991 Wang ACC 5,118,494 06/02/1992 Schultz ADD 5,122,127 06/16/1992 Stanley AEE 5,122,376 06/16/1992 Aliverti AFE 5,179,079 01/12/1993 Hansen et al. 514 4						
				Patentee	Class	Subclass	Date If Appro
/////							
1	AAA	5,006,343	04/09/1991	Benson			
	ABB	5,011,678	04/30/1991	Wang			
	ACC	5,118,494	06/02/1992	Schultz			
	ADD	5,122,127	06/16/1992	Stanley			
	AEE	5,122,376	06/16/1992	Aliverti			
	AFF	5,179,079	01/12/1993	Hansen et al.	514	4	
	AGG	5,192,548	03/09/1993	Velasquez et al.			
	АНН	5,200,393	04/06/1993	Weiner			
O V	AII	5,202,129	04/13/1993	Samejima et al.	424	489	
XX	AJJ	5,254,330	10/19/1993	Ganderton et al.			
	AKK	5,260,306	11/09/1993	Boardman et al.			
	ALL	5,284,656	02/08/1994	Platz et al.	424	435	
	AMM	5,288,498	02/22/1994	Stanley et al.			
	ANN	5,320,094	06/14/1994	Laube et al.	128	203.12	•
	AOO	5,341,800	08/30/1994	Clark et al.	128	203.15	
	APP	5,348,730	09/20/1994	Greenleaf			
	AQQ	5,349,947	09/27/1994	Newhouse et al.	128	203.21	
	ARR	5,352,461	10/04/1994	Feldstein et al.	424	493	
	ASS	5,354,562	10/11/1994	Platz et al.	424	489	
	ATT	5,364,838	11/15/1994	Rubsamen	514	3	
	AUU	5,376,359	12/1994	Johnson			
	AVV	5,376,386	12/27/1994	Ganderton et al.			
	AWW	5,384,133	01/24/1995	Boyes et al.			
	AXX	5,384,133	01/24/1995	Bäckström et al.			

Examiner Signature // (/////////////////////////////////	Date Considered 0
Lewix hyllon	2-1-06
EXAMINER: Initials citation considered. Draw line through citation if no	t in conformance and not considered. Include copy of this form with
next communication to applicant	

10-792201

Sheet <u>3</u> of <u>10</u>

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attomey's Docket No. 06275-004003	Application No.	
ł		Applicant Bäckström et al.		
(Use several st	neets if necessary)	Filing Date	Group Art Unit	

			U.S. Patent	Documents	-		
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appro priate
ZZ	AYY	5,419,315	05/30/1995	Rubsamen	128	200.14	
	AZZ	5,437,271	08/01/1995	Hodson et al.			
	BA	5,437,271	08/01/1995	Bäckström et al.			
	ВВ	5,451,569	09/19/1995	Wong et al.	514	3	
	BC	5,458,135	10/17/1995	Patton et al.	128	200.14	
	BD	5,474,759	12/1995	Fassberg et al.			
	BE	5,482,032	01/09/1996	Smith et al.			
	BF	5,482,706	01/09/1996	Igari et al.			
1)	BG	5,506,203 C1	04/1996	Bäckström et al.			
0	ВН	5,514,670	06/07/1996	Friedman			
	BI	5,518,998 C1	02/2001	Bäckström et al.			
	BJ	5,607,915	03/04/1997	Patton	514	12	
	BK	5,658,878	08/1997	Bäckström et al.			
	BL	5,661,130	08/26/1997	Meezan et al.	514	25	
	ВМ	5,707,644	01/13/1998	Jillem			
	BN	5,730,969	03/24/1998	Hora et al.	424	85.1	
	ВО	5,747,445	05/1988	Bäckström et al.			
	ВР	5,814,607	09/29/1998	Patton	514	12	
	BQ	5,830,853	11/1998	Bäckström et al.			
	BR	5,858,968	01/1999	Weiner et al.			
	BS	5,952,008	09/1999	Bäckström et al.			
	ВТ	5,997,848	12/07/1999	Patton et al.	424	46	
	BU	6,004,574	12/1999	Bäckström et al.			
	BV	6,051,256	04/18/2000	Platz et al.	424	489	
2/1	BW	6,165,976	12/2000	Bäckström et al.			

	$\Box \cap \cap$		
Examiner Signature / / ,		Date Considered	
1 /d V	14/h 600	71-	$\Lambda \Lambda$
LURNIA.	$ \sim$ \sim \sim \sim \sim	2 -1	00
EXAMINER: Initials citation conside	ed. Draw line through citation if n	ot in conformance and not considered	I. Include copy of this form with
next communication to applicant.			
		Subs	stitute Disclosure Form (PTO-1449)

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attomey's Docket No. 06275-004003	Application No.		
by A	closure Statement pplicant	Applicant Bäckström et al.			
(Use several si	heets if necessary)	Filing Date	Group Art Unit		
(37 CFR §1.98(b))					

	U.S. Patent Documents						
Examiner	Desig. ID	Document Number	Publication Date	Detentes	Class	Cubalaga	Filing Date If Appro
ZH C	BX	6,306,440	10/2001	Patentee Bäckström et al.	Class	Subclass	priate
	BY	6,436,902 B1	8/2002	Bäckström et al.			
XX no	BZ	6,524,557	02/2003	Bäckström et al.			
	BAA	6,534,557					
XX.	BBB	20030064928 A1		Bäckström et al.			
X	&CC-	08/601,005					
X	BDD	08/736,267					
X	BEE	-08/906 ,825					
X	BFF	08/960,093					
X	BGG	09/072,7 17					
X	внн	09/158,554					
X'	BII	-09/383,590 -					
X	BII	09/665,58 5					
	-BKK-	09/731,429					-
X	BLL	09/783,18 9					
X	BMM_	10/224,522					
_ / X	BNN.	10/401,157					
X	BOO	1 0/401,1 81					

	Foreign Patent Documents or Published Foreign Patent Applications							
Examiner	Desig.	Document	Publication	Country or			Transl	
Initial	ID	Number	Date	Patent Office	Class	Subclass	Yes	No
XX	BPP	0 023 359	07/29/1980	Europe				
	BQQ	0 055 041	12/03/1981	Europe				
	BRR	0 122 036	10/17/1984	Europe				
	BSS	0 128 831	12/19/1984	Europe				
\bigvee	ВТТ	Ø133 252/A3	02/1985	Europe				
Examiner Sign	nature	1/ ////		Date Considered				

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Disclosure Form (PTO-1449)

Substitute Form PTO-1449 (Modified)					
by A	closure Statement pplicant	Applicant Bäckström et al.			
(Use several sheets if necessary)		Filing Date	Group Art Unit		
(37 CFR §1.98(b))					

	Foreign Patent Documents or Published Foreign Patent Applications							
Examiner	Desig.	Document	Publication	Country or			Translation	
Initial/)	ID	Number	Date	Patent Office	Class	Subclass	Yes	No
	BUU	0 200 383	04/07/1986	Europe				
	BVV	0 225 189	11/28/1986	Europe				
	BWW	0 272 0978	06/22/1988	Europe		,		-
	BXX	0 312 052 A1	.10/1987	Europe				
	BYY	0 360 340	03/28/1990	Europe				
	BZZ	0 364 235 A1	04/1988	Europe				
	CA	0 383 751	09/1994	Europe				
	СВ	0 455 463	11/06/1991	Europe				
	CC	1,242,211	08/11/1971	United Kingdom				
	CD	1,520,247	08/02/1978	United Kingdom				
	CE	1,527,605	10/04/1976	United Kingdom				
	CF	1,569,611	06/18/1980	United Kingdom				
	CG	2,115,065	06/11/1993	Canada				
	СН	43556/93	01/04/1994	Australia				
	CI	8 007 820-7	11/17/1986	Sweden				
	CJ	9 302 198-8	06/1993	Sweden				
	CK	9 400 371-2	02/1994	Sweden				
Avo	CL	DD 261 096 A1	10/19/1988	Germany				
n of	СМ	GB 837,465	06/15/1960	Great Britain				
St	CN	Hei 4-149126	05/22/1992	Japan				
y K	СО	Hei 4-41421	02/12/1992	Japan				
~	CP	JP1117825	02/10/1987	Japan				
X	CQ	JP4041421	06/1990	Japan				
X	CR	JP4149126	1992	Japan				
Las	CS	JP632932	07/01/1988	Japan				
Dock	СТ	WO 87/05213 A1	09/1987	WIPO				
I	CU	WO 88/09163	12/01/1998	PCT				

Examiner Signature	Date Considered 6
Lewid Ly Klan	2-1-06
EXAMINER: Initials citation considered. Draw line through citation if no next communication to applicant	of in conformance and not considered. Include copy of this form with

	Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 06275-004003	Application No.	
		closure Statement	Applicant Bäckström et al.		
(Use several sheets if necessary)		Filing Date	Group Art Unit		
	(37 CFR §1.98(b))				

	Foreign Patent Documents or Published Foreign Patent Applications							
Examiner (Initial)	Desig.	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Trans Yes	lation No
	CV	WO 90/04962	05/17/1990	PCT				
	CW	WO 90/07333	04/12/1990	PCT				
	СХ	WO 91/16038	10/31/1991	PCT				
	CY	WO 91/16882	11/14/1991	PCT				
	CZ	WO 91/16929	11/14/1991	PCT				
	CAA	WO 91/18091 A1	11/19/1991	PCT				
	СВВ	WO 92/04069	03/19/1992	PCT				
00	CCC	WO 92/06704	04/30/1992	PCT				
Sh	CDD	WO 92/08446	05/29/1992	PCT				
	CEE	WO 93/25198	12/23/1993	PCT				
	CFF	WO 94/07514	04/14/1994	PCT				
	CGG	WO 94/22461	10/13/1994	PCT				
	СНН	WO 95/00128	01/1995	PCT				
	CII	WO 95/00151	01/05/1995	PCT				
	CJJ	WO 96/19206	06/1996	PCT				
	CKK	WO 96/19207	06/1996	PCT				
XX	CLL	WO 97/10850	03/27/1997	PCT				

	Other Documents (include Author, Title, Date, and Place of Publication)				
Examiner					
Initial	Desig. ID	Document			
"Diabetes Mellitus" Ch. W		"Diabetes Mellitus" Ch. KI in Scientific American Medicine, Scientific American, Inc. (1993)			
\sim		Allenby et al. "The Absorption of Insulin Across the Respiratory Tract of the Guinea-Pig (U)" The Aersol Society, Fourth Annual Conference 129-134 (1990)			
COO Almer et al. L		Almer et al. Diabetes Research and Clin. Pract. 5:s163 (1988)			
		Aungst et al, "Comparison of Nasal," The Journal of Pharmacology and Experimental Therapeutics 244:23-27 (1987)			
\searrow		Aungst et al. "Comparison of the Effects of Various Transmucosal Absorption Promoters on Buccal Insulin Delivery" Int. J. Pharm. 53(3):227-235 (1989)			
CRR Barbaud Clinical Reviews in Allergy		Barbaud Clinical Reviews in Allergy and Immunology 13(3):253-263 (1995)			

Examiner Signature Low I & Man	Date Considered 2 -1 -06
EXAMINER: Initials citation considered. Draw line through citation if n next communication to applicant.	not in conformance and not considered. Include copy of this form with
	Substitute Disclosure Form (PTO-1449)

	/	
10/	792	701
1 /	192	

Sheet <u>7</u> of <u>10</u>

Substitute Form PTO-1449 U.S. Department of Comm (Modified) Patent and Trademark C		Attorney's Docket No. 06275-004003	Application No.
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Bäckström et al.	
		Filing Date	Group Art Unit

Other Documents (include Author, Title, Date, and Place of Publication)					
Examiner					
Initial	Desig. ID	Document Björk et al. "Degradable Starch Microspheres as a Masal Delivery System for Insulin" Int. J.			
27	Ċ 98 -	Pharm. 42.233-238 (1988)			
200	CTT	Bjork et al., "Characterization of degradable starch" Int. J. Pharmaceutics 62:187-192 (1990)			
X	CUO	Björk "Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy" Acta Univ. Uppsala 103 (1993)			
	CVV	Björk "Starch Microspheres as a Nasal Delivery System for Drugs" Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy 103 (1993)			
X	CWW	Brange et al "Monomeric Insulins and their Experimental and Clinical Implications" Diabetes Care 13:923-954 (1990)			
1 m	CXX	Byron et al., "Drug Delivery via the Respiratory" Journal of Aerosol Medicine 7:49-75 (1994)			
SK	CYY	Chandler et al. "Nasal Absorption Rats. II. Effect of Enhancers on Insulin Absorption and Nasal Histology" Int. J. Pharmaceutics 76:61-70 (1991)			
X	CZZ	Chien et al. "Intranasal Drug Delivery for Systemic Medications" CRC Critical Reviews in Therapeutic Drug Carrier Systems 4:67-194 (1987)			
SX	DA	Chien et al, "Potential Developments in" Drug Development and Industrial Pharmacy 15(10):1601-1634 (1989)			
	DB	Colthorpe et al, "The Pharmacokinetics" Pharmaceutical Research 9(6):764-768 (1992)			
	DC	Cutie et al. "The Role of the Dispersing Agents in Inhalation and Intranasal Aerosol Suspensions" Aerosol. Age 30:52-54 (1985)			
	DD	Dahlbäck et al. "Regional Administration of Drugs to the Rabbit Respiratory Tract, Effects on Absorption" J. Aerosol. Medicine 1:222-223 (1988)			
	DE	Damsay et al. Diabetes Res. and Clin. Pract. 5:s163 (1988)			
	DF	Dempster et al. "Anabolic Actions of Parathyroid Hormone on Bone" Endocrine Reviews 14: 690-709 (1993).			
	DG	Edman et al. "Routes of Delivery: Case Studies" Advanced Drug Delivery Reviews 8:165-177 (1992)			
V	DH	Elliott et al. "Parenteral absorption of insulin" Aust. Paediatr. J. 23:293-297 (1987)			
DR	DI	Eppstein et al. "Alternative Delivery Systems for Peptides and Proteins as Drugs" CRC Critical Reviews in Therapeutic Drug Carrier Systems 5:99-139 (1988)			
\searrow	DI	Gonf et al., "Palmitoylcarnitime, a surface-active metabolite" FEBS Lett. 390:1-5 (1996)			
	DK	Gordon et al. "Nasal Absorption of Insulin: Enhancement by Hydrophobic Bile Salts" <i>Proc. Natl. Acad. Sci. USA</i> 82:7419-7423 (1985)			
My.	DL	Hirai et al. "Effect of Surfactants on the Nasal Absorption of Insulin in Rats" Int. J. Pharmaceutics 9:165-172 (1981)			
LK.	DM	Hoover et al, "Peptides are Better," Pharmaceutical Research 9(8):1103-1106 (1992)			
X		Igawa et al. "Effect of Absorption Promoters in Intranasal Administration of Human Fibroblast Interferon as a Powder Dosage Form in Rabbits" Chem. Pharm. Bull. 37:418-421 (1989)			
SX	DO	Jacobs et al. "The Pharmacodynamics and" Diabetes 42:1649-1655 (1993)			
	_				

Examiner Signature Low Low Live Miles	Date Considered 2 -1 - 06
EXAMINER: Initials citation considered. Draw line through citation if no next communication to applicant.	t in conformance and not considered. Include copy of this form with

	Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 06275-004003	Application No.
Information Disclosure Statement by Applicant		Applicant Bäckström et al.		
	(Use several sheets if necessary) (37 CFR §1.98(b))		Filing Date	Group Art Unit

Design D	Other Documents (include Author, Title, Date, and Place of Publication)			
DP Jaegfeldt et al. "Particle size distribution from different modifications of Turbuhaler" Proceedings of an international workshop on a new inhaler 21-22-90-99 (1987) DQ Jones "Pulmonary Absorption of Insulin" Ph.D. Thesis, Welsh School of Pharmacy, University of Wales, United Kingdom (1998) DR Kalinkova International Journal of Pharmaceutics 187(1):1-15 (1999) DS Kähler et al. "Pulmonary Administration" Diabetes 33:475 A (1984) Kähler et al. "Non radioactive procedure for the measurement of lung permeability: inhalation of insulin" Atemw. Lungenkrkh. Jahrgang 13:230-232 (1987) DU Köhler "Aerosols for Systemic Treatment" Lung Supp 1:677-684 (1990) Kömada et al. "Intratracheal Delivery of Peptide and Protein Agents: Absorption from Solution and Dry Powder by Rat Lung" J. Pharm. Sci. 83:863-867 (1994) DW Lisker "The Diabetes Control and Complications Thial" N. Engl. J. Med. 329:1035-1036 (1993) Lake et al. "Residinary Study of the Effect of Inhulin Aerosol Delivered by Oral Inhalation in Diabetes Patients" J. Mal. 269:2106-2109 (1993) Lecluyse et al. "In Vitro Effects of Long-Chain Acylcarnitines on the Permeability, Transcpithelial Electrical Resistance and Morphology of Rat Colonic Mucosa" J. Pharmacol. Exp. Ther. 265(2):955-962 (1993) DZ Lee et al. "Development of an Aerosol Dosage Form Containing Insulin" J. Pharmacoul. Exp. Ther. 265(2):957-962 (1993) DA Deveral American Chemitical Society 301-309 (1987) DBB Lee et al. "Intransal Bioavailability of Insulin Powder Formulations: Effect of Permeation Enhancers for Facilitation of Peptide and Protein Drug Absorption" Critical Rev. Therapeut. Drug Carrier Systems 8:191-192 (1991) DDC Lee et al. "Wulmonary Delivery of Free" Pharm. Biopharm. 39:216-221 (1993) DEE Liu et al. "Pulmonary Delivery of Free" Pharmaceutical Research 10:228-232 (1993) DBE Liu et al. "Replace of the Promoting Effects of Medium Chain Fatty Acid Salts on the Nasal Xbsorption of Insulin in Rats". J. Pharm. 10:624-631 (1987) DBB Migate et al. "Effects of Vagious Absor	Examiner			
DP Proceedings of an international workshop on a new inhaler 21-22:90-99 (1987) DQ Jones "Pulmonary Absorption of Insulin" Ph.D. Thesis, Welsh School of Pharmacy, University of Wales, United Kingdom (1998) DR Kalinkova International Journal of Pharmaceutics 187(1):1-15 (1999) DS Köhler et al. "Pulmonary Administration" Diabetes 33:75A (1984) DT Köhler et al. "Non radioactive procedure for the measurement of lung permeability: inhalation of insulin" AtemwLungenkrkh., Jahrgang 13:230-232 (1987) DU Köhler "Aerosols for Systemic Treatment" Lung Supp 1:677-684 (1990) Womada et al. "Intratracheal Delivery of Peptide and Protein Agents: Absorption from Solution and Dry Powder by Rat Lung" J. Pharm. Sci. 83:863-867 (1994) Lysker "The Diabetes Control and Complications-Trial" N. Engl. J. Med. 329:1035-1036 (1993) Lestury et al. "Rysiffminary Shady of the Efficacy of Inhulin Aerosol Delivered by Oral Inhalation inhibiabetic Patients" JAMA 269:2106-2109 (1993) Lecturyse et al. "In Vitro Effects of Long-Chain Acylcamitines on the Permeability Transepithelial Electrical Resistance and Morphology of Rat Colonic Mucosa" J. Pharmacol. Exp. Ther. 265(2):955-962 (1993) DZ Lee et al. "Development of an Aerosol Dosage Form Containing Insulin" J. Pharmaceutical Sciences 65(4):567-574 (1976) DAA De-er al. American Chemical Society 301-309 (1987) DBB Lee et al. "Intransas Bioavailability of Insulin Powder Formulations: Effect of Permeation Enhancer-to-Protein Ratio J. Pharm. Sci. 80:725-729 (1991) DCC Lee et al. "Intransas Bioavailability of Insulin Powder Formulations: Effect of Permeation Enhancers for Facilitation of Peptide and Protein Drug Absorption" Critical Rev. Therapeut. Drug Carrier Systems 8:191-192 (1991) DCC Lie et al. "Pulmonary Delivery of Free" Pharmaceutical Research 10:228-232 (1993) DEE Liu et al. "Pulmonary Delivery of Free" Pharmaceutical Research 10:228-232 (1993) DEF Scheep" J. Pharm. Sci. 76(5):351-355 (1987) Missima et al. "Sandies on the Promoting Effects of Medium Chain Fatty Ac	(nitial			
DR Kalinkova International Journal of Pharmaceutics 187(1):1-15 (1999) DR Kalinkova International Journal of Pharmaceutics 187(1):1-15 (1999) DS Köhler et al. "Non radioactive procedure for the measurement of lung permeability: inhalation of insulin" *ItemwLungenkrkh., Jahrgang 13:330-232 (1987) DU Köhler "Aerosols for Systemic Treatment" *Lung Supp 1:677-684 (1990) Kömada et al. "Intratracheal Delivery of Peptide and Protein Agents: Absorption from Solution and Dry Powder by Rat Lung" *J. Pharm. Sci. 83:863-867 (1994) DW Lisker "The Diabetes Control and Complications Thail" *N.Engl. J. Med. 329:1035-1036 (1993) Laube et al. "Endifininary Study of the Effects of Inquiin Aerosol Delivered by Oral Inhalation in Diabetic Patients" *J.MM 269:2106-2109 (1993) Lecluyse et al. "In Vitro Effects of Long-Chain Acylcarnitines on the Permeability, Transepithelial Electrical Resistance and Morphology of Rat Colonic Mucosa" *J. Pharmacol. Exp. Ther. 265(2):955-962 (1993) DZ Lee et al. "Development of an Aerosol Dosage Form Containing Insulin" *J. Pharmaceutical Sciences 65(4):567-574 (1976) DAA Dee et al. "Intranasal Bioavailability of Insulin Powder Formulations: Effect of Permeation Enahancer-to-Protein Ratio" *J. Pharm. Sci. 80:725-729 (1991) DCC Absorption" *Critical Rev. Therapeut. Drug Carrier Systems 8:191-192 (1991) DDD Li et al. "Effect of a" Eur. J. Pharm. Biopharm. 39:216-221 (1993) DEE Liu et al. "Pulmonary Delivery of Free" *Pharmaceutical Research 10:228-232 (1993) DFF Schere and *Schere and *S	DIZ O	DP	Proceedings of an international workshop on a new inhaler 21-22:90-99 (1987)	
DS Köhler et al. "Pulmonary Administration" Diabetes 33:75A (1984)	O SK	DQ		
DT Köhler et al. "Non radioactive procedure for the measurement of lung permeability: inhalation of insulin" AtemwLungenkrkh., Jahrgang 13:230-232 (1987)	XX	DR	Kalinkova International Journal of Pharmaceutics 187(1):1-15 (1999)	
insulin" AtemwLungenkrkh., Jahrgang 13:230-232 (1987) DU Köhler "Acrosols for Systemic Treatment" Lung Supp 1:677-684 (1990) Normada et al. "Intratracheal Delivery of Peptide and Protein Agents: Absorption from Solution and Dry Powder by Rat Lung" J. Pharm. Sci. 83:863-867 (1994) Løsker "The Diabetes Control and Complications Trial" N.Engl. J. Med. 329:1035-1036 (1993) Løsher "The Diabetes Control and Complications Trial" N.Engl. J. Med. 329:1035-1036 (1993) Løsher "The Diabetes Control and Complications Trial" N.Engl. J. Med. 329:1035-1036 (1993) Løsher "The Diabetes Control and Complications Trial" N.Engl. J. Med. 329:1035-1036 (1993) Løsher "The Diabetes Control and Complications Trial" N.Engl. J. Med. 329:1035-1036 (1993) Lect al. "In Vitro Effects of Long-Chain Acylcarnitines on the Permeability, Transepithelial Electrical Resistance and Morphology of Rat Colonic Mucosa" J. Pharmacol. Exp. Ther. 265(2):955-962 (1993) Lee et al. "Development of an Aerosol Dosage Form Containing Insulin" J. Pharmacol. Exp. Ther. 265(2):955-962 (1993) DAA De-et al. American Chemical-Society 301-309 (1987) Lee et al. "Intranasal Bioavailability of Insulin Powder Formulations: Effect of Permeation Enahancer-to-Protein Ratio" J. Pharm. Sci. 80:725-729 (1991) DCC Lee et al. "Intranasal Bioavailability of Insulin Powder Formulations: Effect of Permeation Enahancer-to-Protein Ratio" J. Pharm. Sci. 80:725-729 (1991) DDD Li et al. "Effects of Enahancers for Facilitation of Peptide and Protein Drug Absorption" Critical Rev. Therapeut. Drug Carrier Systems 8:191-192 (1991) DEE Liu et al. "Effects of Sodium Taurodihydrofusidate on Nasal Absorption of Insulin in Sheep" J. Pharm. Sci. 76(5):351-355 (1987) DGG Mishme et al. "Effects of Sodium Taurodihydrofusidate on Nasal Absorption of Insulin in Rats" J. Pharma. 10:624-631 (1987) DGG Mishme et al. "Effects of Various Absorption Promoters on Pulmonary Absorption of Drugs with Different Moteculal Weighla: Ball. Pharm. Bull. 16:269-262 (1993) Moses et al. "Insulin Administ	X		Köhler et al. "Pulmonary Administration" Diabetes 33:75 A (1984)	
DV Komada et al. "Intratracheal Delivery of Peptide and Protein Agents: Absorption from Solution and Dry Powder by Rat Lung" J. Pharm. Sci. 83:863-867 (1994) DW	D	DT		
and Dry Powder by Rat Lung" J. Pharm. Sci. 83:863-867 (1994) DW Lasker "The Diabetes Control and Complications Trial" N.Engl. J. Med. 329:1035-1036 (1993) Lasker "The Diabetes Control and Complications Trial" N.Engl. J. Med. 329:1035-1036 (1993) Labe et al. "Rightminary Shedy of the Efficacy of Inhulin Aerosol Delivered by Oral Inhalation in Diabetic Patients" J.M.M. 269:2106-2109 (1993) Lecluyse et al. "In Vitro Effects of Long-Chain Acylcarnitines on the Permeability, Transepithelial Electrical Resistance and Morphology of Rat Colonic Mucosa" J. Pharmacol. Exp. Ther. 265(2):955-962 (1993) Lee et al. "Development of an Aerosol Dosage Form Containing Insulin" J. Pharmaceutical Sciences 65(4):567-574 (1976) DAA Desertal American Chemical Society 301-309 (1987) DBB Lee et al. "Intranasal Bioavailability of Insulin Powder Formulations: Effect of Permeation Enahancer-to-Protein Ratio" J. Pharm. Sci. 80:725-729 (1991) DCC Lee et al. "Mucosal Penetration Enhancers for Facilitation of Peptide and Protein Drug Absorption" Critical Rev. Therapeut. Drug Carrier Systems 8:191-192 (1991) DDD Li et al. "Effect of a" Eur. J. Pharm. Biopharm. 39:216-221 (1993) DEE Liu et al. "Pulmonary Delivery of Free" Pharmaceutical Research 10:228-232 (1993) DFF Longnecker et al. "Effects of Sodium Taurodihydrofusidate on Nasal Absorption of Insulin in Sheep" J. Pharm. Sci. 76(5):351-355 (1987) Misjaima et al. "Effects of Sodium Taurodihydrofusidate on Nasal Absorption of Insulin in Rats" J. Pharma. 10:624-631 (1987) DHH Mizgala et al. "Renal Handling of Phosphate" Physiological Reviews 65(2):431-466 (1985) Morga et al. "Effects of Various Absorption Promoters on Pulmonary Absorption of Drugs with Different Moleculal Weights." Biol. Pharm. Bull. 16:269-262 (1993) Nagai et al. "Insulin Administered Intranasally as an Insulin-Bile Salt Aerosol" Diabetes 32:1040-1047 (1983) Nagai et al. "Powder Dosage Form of Insulin for Nasal Administration" J. Controlled Release 1:15-22 (1984)	Set	DU	Köhler "Aerosols for Systemic Treatment" Lung Supp 1:677-684 (1990)	
I Jaube et al. "Rightminary Shedy of the Efficacy of Inkulin Aerosol Delivered by Oral Inhalation in Diabetic Patients" JAMA 269:2106-2109 (1993) Lecluyse et al. "In Vitro Effects of Long-Chain Acylcarnitines on the Permeability, Transepithelial Electrical Resistance and Morphology of Rat Colonic Mucosa" J. Pharmacol. Exp. Ther. 265(2):955-962 (1993) DZ Lee et al. "Development of an Aerosol Dosage Form Containing Insulin" J. Pharmaceutical Sciences 65(4):567-574 (1976) DAA Deveral American Chemical Society 301-309 (1987) Lee et al. "Intranasal Bioavailability of Insulin Powder Formulations: Effect of Permeation Enhancer-to-Protein Ratio" J. Pharm. Sci. 80:725-729 (1991) DCC Lee et al. "Mucosal Penetration Enhancers for Facilitation of Peptide and Protein Drug Absorption" Critical Rev. Therapeut. Drug Carrier Systems 8:191-192 (1991) DDD Li et al. "Effect of a" Eur. J. Pharm. Biopharm. 39:216-221 (1993) DEE Liu et al. "Pulmonary Delivery of Free" Pharmaceutical Research 10:228-232 (1993) DFF Longnecker et al. "Effects of Sodium Taurodihydrofusidate on Nasal Absorption of Insulin in Sheep" J. Pharm. Sci. 76(5):351-355 (1987) Mishma et al. "Stadies on the Promoting Effects of Medium Chain Fatty Acid Salts on the Nasal Absorption of Insulin in Rats" J. Pharma. 10:624-631 (1987) DHH Mizgala et al. "Renal Handling of Phosphate" Physiological Reviews 65(2):431-466 (1985) More et al. "Insulin Administered Intranasally as an Insulin-Bile Salt Aerosol" Diabetes 32:1040-1047 (1983) Nagai et al. "Powder Dosage Form of Insulin for Nasal Administration" J. Controlled Release 1:15-22 (1984)	Sh	DV		
in Diabetic Patients" JAMA 269:2106-2109 (1993) Lecluyse et al. "In Vitro Effects of Long-Chain Acylcarnitines on the Permeability, Transepithelial Electrical Resistance and Morphology of Rat Colonic Mucosa" J. Pharmacol. Exp. Ther. 265(2):955-962 (1993) DZ Lee et al. "Development of an Aerosol Dosage Form Containing Insulin" J. Pharmaceutical Sciences 65(4):567-574 (1976) DAA Lee et al. "Intranasal Bioavailability of Insulin Powder Formulations: Effect of Permeation Enahancer-to-Protein Ratio" J. Pharm. Sci. 80:725-729 (1991) DCC Lee et al. "Mucosal Penetration Enhancers for Facilitation of Peptide and Protein Drug Absorption" Critical Rev. Therapeut. Drug Carrier Systems 8:191-192 (1991) DDD Li et al. "Effect of a" Eur. J. Pharm. Biopharm. 39:216-221 (1993) DEE Liu et al. "Pulmonary Delivery of Free" Pharmaceutical Research 10:228-232 (1993) DFF Dord Mishima et al. "Strdies of the Promoting Effects of Medium Chain Fatty Acid Salts on the Nasal Absorption of Insulin in Rats" J. Pharma. 10:624-631 (1987) DHH Mizgala et al. "Renal Handling of Phosphate" Physiological Reviews 65(2):431-466 (1985) DJJ More et al. "Effects of Various Absorption Promoters on Pulmonary Absorption of Drugs with Different Moteculal Weighth." Brd. Pharm. Bull. 16:269-262 (1993) Noses et al. "Insulin Administered Intranasally as an Insulin-Bile Salt Aerosol" Diabetes 32:1040-1047 (1983) Nagai et al. "Powder Dosage Form of Insulin for Nasal Administration" J. Controlled Release 1:15-22 (1984)	X	DW-		
DY Transepithelial Electrical Resistance and Morphology of Rat Colonic Mucosa" J. Pharmacol. Exp. Ther. 265(2):955-962 (1993) DZ Lee et al. "Development of an Aerosol Dosage Form Containing Insulin" J. Pharmaceutical Sciences 65(4):567-574 (1976) DAA Deveral American Chemical Society 301-309 (1987) Lee et al. "Intranasal Bioavailability of Insulin Powder Formulations: Effect of Permeation Enahancer-to-Protein Ratio" J. Pharm. Sci. 80:725-729 (1991) DCC Lee et al. "Mucosal Penetration Enhancers for Facilitation of Peptide and Protein Drug Absorption" Critical Rev. Therapeut. Drug Carrier Systems 8:191-192 (1991) DDD Li et al. "Effect of a" Eur. J. Pharm. Biopharm. 39:216-221 (1993) DEE Liu et al. "Pulmonary Delivery of Free" Pharmaceutical Research 10:228-232 (1993) DFF Longnecker et al. "Effects of Sodium Taurodihydrofusidate on Nasal Absorption of Insulin in Sheep" J. Pharm. Sci. 76(5):351-355 (1987) Mishima et ah. "Stadies on the Promoting Effects of Medium Chain Fatty Acid Salts on the Nasal Absorption of Insulin in Rats" J. Pharma. 10:624-631 (1987) DHH Mizgala et al. "Renal Handling of Phosphate" Physiological Reviews 65(2):431-466 (1985) Morita et al. "Effects of Various Absorption Promoters on Pulmonary Absorption of Drugs with Different Molecular Weights" Biol. Pharm. Bull. 16:269-262 (1993) Moses et al. "Insulin Administered Intranasally as an Insulin-Bile Salt Aerosol" Diabetes 32:1040-1047 (1983) Nagai et al. "Powder Dosage Form of Insulin for Nasal Administration" J. Controlled Release 1:15-22 (1984)	X	-DX	in Diabetic Patients" JAMA 269:2106-2109 (1993)	
DAA Dee et al. American Chemical Society 301-309 (1987) DBB Lee et al. "Intranasal Bioavailability of Insulin Powder Formulations: Effect of Permeation Enahancer-to-Protein Ratio" J. Pharm. Sci. 80:725-729 (1991) DCC Lee et al. "Mucosal Penetration Enhancers for Facilitation of Peptide and Protein Drug Absorption" Critical Rev. Therapeut. Drug Carrier Systems 8:191-192 (1991) DDD Li et al. "Effect of a" Eur. J. Pharm. Biopharm. 39:216-221 (1993) DEE Liu et al. "Pulmonary Delivery of Free" Pharmaceutical Research 10:228-232 (1993) DFF Longnecker et al. "Effects of Sodium Taurodihydrofusidate on Nasal Absorption of Insulin in Sheep" J. Pharm. Sci. 76(5):351-355 (1987) Mishima et al. "Skalies on the Promoting Effects of Medium Chain Fatty Acid Salts on the Nasal Absorption of Insulin in Rats" J. Pharma. 10:624-631 (1987) DHH Mizgala et al. "Renal Handling of Phosphate" Physiological Reviews 65(2):431-466 (1985) Morta et al. "Effects of Various Absorption Promoters on Pulmonary Absorption of Drugs with Different Motecular Weights" Biol. Pharm. Bull. 16:269-262 (1993) DJJ Moses et al. "Insulin Administered Intranasally as an Insulin-Bile Salt Aerosol" Diabetes 32:1040-1047 (1983) Nagai et al. "Powder Dosage Form of Insulin for Nasal Administration" J. Controlled Release 1:15-22 (1984)	M	DY	Transepithelial Electrical Resistance and Morphology of Rat Colonic Mucosa" J. Pharmacol. Exp. Ther. 265(2):955-962 (1993)	
DBB Lee et al. "Intranasal Bioavailability of Insulin Powder Formulations: Effect of Permeation Enahancer-to-Protein Ratio" J. Pharm. Sci. 80:725-729 (1991) DCC Lee et al. "Mucosal Penetration Enhancers for Facilitation of Peptide and Protein Drug Absorption" Critical Rev. Therapeut. Drug Carrier Systems 8:191-192 (1991) DDD Li et al. "Effect of a" Eur. J. Pharm. Biopharm. 39:216-221 (1993) DEE Liu et al. "Pulmonary Delivery of Free" Pharmaceutical Research 10:228-232 (1993) DFF Longnecker et al. "Effects of Sodium Taurodihydrofusidate on Nasal Absorption of Insulin in Sheep" J. Pharm. Sci. 76(5):351-355 (1987) Mishima et al. "Stadies on the Promoting Effects of Medium Chain Fatty Acid Salts on the Nasal Absorption of Insulin in Rats" J. Pharma. 10:624-631 (1987) DHH Mizgala et al. "Renal Handling of Phosphate" Physiological Reviews 65(2):431-466 (1985) Morita et al. "Effects of Various Absorption Promoters on Pulmonary Absorption of Drugs with Different Moleculal Weights" Biol. Pharm. Bull. 16:269-262 (1993) DJJ Moses et al. "Insulin Administered Intranasally as an Insulin-Bile Salt Aerosol" Diabetes 32:1040-1047 (1983) Nagai et al. "Powder Dosage Form of Insulin for Nasal Administration" J. Controlled Release 1:15-22 (1984)	DZ Lee et al. "Development of an Sciences 65(4):567-574 (1976) DAA Decertal American Chemical			
DBB Enahancer-to-Protein Ratio" J. Pharm. Sci. 80:725-729 (1991) Lee et al. "Mucosal Penetration Enhancers for Facilitation of Peptide and Protein Drug Absorption" Critical Rev. Therapeut. Drug Carrier Systems 8:191-192 (1991) DDD Li et al. "Effect of a" Eur. J. Pharm. Biopharm. 39:216-221 (1993) DEE Liu et al. "Pulmonary Delivery of Free" Pharmaceutical Research 10:228-232 (1993) DFF Longnecker et al. "Effects of Sodium Taurodihydrofusidate on Nasal Absorption of Insulin in Sheep" J. Pharm. Sci. 76(5):351-355 (1987) Mishima et al. "Statlies on the Promoting Effects of Medium Chain Fatty Acid Salts on the Nasal Absorption of Insulin in Rats" J. Pharma. 10:624-631 (1987) DHH Mizgala et al. "Renal Handling of Phosphate" Physiological Reviews 65(2):431-466 (1985) DIL Morita et al. "Effects of Various Absorption Promoters on Pulmonary Absorption of Drugs with Different Moleculal Weights" Biol. Pharm. Bull. 16:269-262 (1993) Moses et al. "Insulin Administered Intranasally as an Insulin-Bile Salt Aerosol" Diabetes 32:1040-1047 (1983) Nagai et al. "Powder Dosage Form of Insulin for Nasal Administration" J. Controlled Release 1:15-22 (1984)			Lee et al. American Chemical Society 301-309 (1987)	
Absorption" Critical Rev. Therapeut. Drug Carrier Systems 8:191-192 (1991) DDD Li et al. "Effect of a" Eur. J. Pharm. Biopharm. 39:216-221 (1993) DEE Liu et al. "Pulmonary Delivery of Free" Pharmaceutical Research 10:228-232 (1993) DFF Longnecker et al. "Effects of Sodium Taurodihydrofusidate on Nasal Absorption of Insulin in Sheep" J. Pharm. Sci. 76(5):351-355 (1987) Mishima et al. "Studies on the Promoting Effects of Medium Chain Fatty Acid Salts on the Nasal Absorption of Insulin in Rats" J. Pharma. 10:624-631 (1987) DHH Mizgala et al. "Renal Handling of Phosphate" Physiological Reviews 65(2):431-466 (1985) Morita et al. "Effects of Various Absorption Promoters on Pulmonary Absorption of Drugs with Different Moleculal Weights" Biol. Pharm. Bull. 16:269-262 (1993) DJJ Moses et al. "Insulin Administered Intranasally as an Insulin-Bile Salt Aerosol" Diabetes 32:1040-1047 (1983) Nagai et al. "Powder Dosage Form of Insulin for Nasal Administration" J. Controlled Release 1:15-22 (1984)		DBB	Enahancer-to-Protein Ratio" J. Pharm. Sci. 80:725-729 (1991)	
DEE Liu et al. "Pulmonary Delivery of Free" Pharmaceutical Research 10:228-232 (1993) DFF Longnecker et al. "Effects of Sodium Taurodihydrofusidate on Nasal Absorption of Insulin in Sheep" J. Pharm. Sci. 76(5):351-355 (1987) Mishima et al. "Straties on the Promoting Effects of Medium Chain Fatty Acid Salts on the Nasal Absorption of Insulin in Rats" J. Pharma. 10:624-631 (1987) DHH Mizgala et al. "Renal Handling of Phosphate" Physiological Reviews 65(2):431-466 (1985) Morita et al. "Effects of Various Absorption Promoters on Pulmonary Absorption of Drugs with Different Molecular Weights" Biol. Pharm. Bull. 16:269-262 (1993) DJJ Moses et al. "Insulin Administered Intranasally as an Insulin-Bile Salt Aerosol" Diabetes 32:1040-1047 (1983) Nagai et al. "Powder Dosage Form of Insulin for Nasal Administration" J. Controlled Release 1:15-22 (1984)	De la	DCC		
DFF Longnecker et al. "Effects of Sodium Taurodihydrofusidate on Nasal Absorption of Insulin in Sheep" J. Pharm. Sci. 76(5):351-355 (1987) Mishima et al. "Statlies on the Promoting Effects of Medium Chain Fatty Acid Salts on the Nasal Absorption of Insulin in Rats" J. Pharma. 10:624-631 (1987) DHH Mizgala et al. "Renal Handling of Phosphate" Physiological Reviews 65(2):431-466 (1985) Morita et al. "Effects of Various Absorption Promoters on Pulmonary Absorption of Drugs with Different Moleculal Weights" Biol. Pharm. Bull. 16:269-262 (1993) Moses et al. "Insulin Administered Intranasally as an Insulin-Bile Salt Aerosol" Diabetes 32:1040-1047 (1983) Nagai et al. "Powder Dosage Form of Insulin for Nasal Administration" J. Controlled Release 1:15-22 (1984)		DDD	Li et al. "Effect of a" Eur. J. Pharm. Biopharm. 39:216-221 (1993)	
Sheep" J. Pharm. Sci. 76(5):351-355 (1987) Mishima et al: "Strdies on the Promoting Effects of Medium Chain Fatty Acid Salts on the Nasal Absorption of Insulin in Rats" J. Pharma. 10:624-631 (1987) DHH Mizgala et al. "Renal Handling of Phosphate" Physiological Reviews 65(2):431-466 (1985) Morita et al. "Effects of Various Absorption Promoters on Pulmonary Absorption of Drugs with Different Molecular Weights" Biol. Physiol. Bull. 16:269-262 (1993) Moses et al. "Insulin Administered Intranasally as an Insulin-Bile Salt Aerosol" Diabetes 32:1040-1047 (1983) Nagai et al. "Powder Dosage Form of Insulin for Nasal Administration" J. Controlled Release 1:15-22 (1984)	No.	DEE	Liu et al. "Pulmonary Delivery of Free" Pharmaceutical Research 10:228-232 (1993)	
Mishima et al: "Studies on the Promoting Effects of Medium Chain Fatty Acid Salts on the Nasal Absorption of Insulin in Rats" J. Pharma. 10:624-631 (1987) DHH Mizgala et al. "Renal Handling of Phosphate" Physiological Reviews 65(2):431-466 (1985) Morita et al. "Effects of Various Absorption Promoters on Pulmonary Absorption of Drugs with Different Molecular Weights" Biol. Pharm. Bull. 16:269-262 (1993) Moses et al. "Insulin Administered Intranasally as an Insulin-Bile Salt Aerosol" Diabetes 32:1040-1047 (1983) Nagai et al. "Powder Dosage Form of Insulin for Nasal Administration" J. Controlled Release 1:15-22 (1984)	DL	DFF		
DHH Mizgala et al. "Renal Handling of Phosphate" Physiological Reviews 65(2):431-466 (1985) Morita et al. "Effects of Various Absorption Promoters on Pulmonary Absorption of Drugs with Different Molecular Weights" Biol. Pharm. Bull. 16:269-262 (1993) Moses et al. "Insulin Administered Intranasally as an Insulin-Bile Salt Aerosol" Diabetes 32:1040-1047 (1983) Nagai et al. "Powder Dosage Form of Insulin for Nasal Administration" J. Controlled Release 1:15-22 (1984)	×	D96/	Mishima et al. "Studies on the Promoting Effects of Medium Chain Fatty Acid Salts on the Nasal	
DJJ Moses et al. "Insulin Administered Intranasally as an Insulin-Bile Salt Aerosol" Diabetes 32:1040-1047 (1983) Nagai et al. "Powder Dosage Form of Insulin for Nasal Administration" J. Controlled Release 1:15-22 (1984)	J.R	DHH		
32:1040-1047 (1983) Nagai et al. "Powder Dosage Form of Insulin for Nasal Administration" J. Controlled Release 1:15-22 (1984)	X	DILE	Different Molecular Weights" Biol. Pharm. Bull. 16:269-262 (1993)	
1:15-22 (1984)	De	DJJ	32:1040-1047 (1983)	
1 1 1 1 1	X	-BAKK/		
DLL Nagano et al. "New Method of Insulin" Jikeikai Med. J. 32:503-506 (1985)	L DL	DLL	Nagano et al. "New Method of Insulin" Jikeikai Med. J. 32:503-506 (1985)	

DLL DLL	Nagano et al. "New Method of In-	sulin" Jikeikai Med. J. 32:503-506 (1985)	
Examiner Signature	1, 1 1/1/1/	Date Considered / /	
	Vilar V Pilada		
L	Lowid Kyldan	211100	
EXAMINER: Initials citation	considered. Draw line through citation if n	ot in conformance and not considered. Include copy of th	is form with
next communication to appl	icant.	,	
		Substitute Disclosure Fo	om (PTO-1449)

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 06275-004003	Application No.
Information Disclosure Statement by Applicant		Applicant Bäckström et al.	
(Use several sh	neets if necessary)	Filing Date	Group Art Unit
(37 CFR §1.98(b))			

	Other Documents (include Author, Title, Date, and Place of Publication)			
Examiner	Desig. ID	Document		
M	DMM	Newman, "Chapter 9: Therapeutic aerosols" Aerosols and the Lung: Clinical and Experimental Aspects, Butterworth & Co., United Kingdom (1984)		
	DNN	O'Hagan et al. "Absorption of Peptides and Proteins from the Respiratory Tract and the Potential for Development of Locally Administered Vaccine" CRC Critical Reviews in Therapeutic Drug Carrier Systems 7:35-97 (1990)		
	DOO	Okumura et al. "Intratracheal delivery of insulin absorption from solution and aerosol by rat lung" International Journal of Pharmaceutics 88:63-73 (1992)		
	DPP	Olanoff et al. "Method to Enhance Intranasal Peptide Delivery" Controlled-Release Technology Pharmaceutical Applications		
Jan	DQQ	Patton et al. "(D) Routes of Delivery: Case Studies" Advanced Drug Delivery Reviews 8:179-196 (1992)		
IK n	O DRR	Patton et al. "Bioavailability of Pulmonary Delivered Peptides and Proteins: α-interferon, Calcitonins and Parathyroid Hormones" Journal of Controlled Release 28:79-85 (1994)		
1	DSS	Pifferi FARMACO 54(1-2):1-14 (1999)		
X	MITT	Pontiroli et al. "Nasal Administration of Glucagon and Human Calcitonin to Healthy Subjects: a Comparison of Powders and Spray Solutions and of Different Enhancing Agents" Eur. J. Clin. Pharmacol. 37:427-430 (1989)		
	שעע	Remington's Pharmaceutical Science, 18th Edition, p. 1079 (1990)		
	DVV	Ruin "Diabetics May Not Need Their Insulin Shots" Sydsvenska (Dagbladet) (1989)		
	DWW	Sakr "A new approach for insulin" International Journal of Pharmaceutics 86:1-7 (1992)		
V	DXX	Salzman et al., "Intranasal Aerosolized Insulin Mixed-Meal Studies and Long-term Use in Type I Diabetes" The New England Journal of Medicine 312:1078-1084 (1985)		
X	DYY Schipper et al. "Nasal Insulin Delivery with Dimethyl-β-Cyclodextrin as an Absorption En in Rabbits: Powder More Effective than Liquid Formulations" Pharmaceutical Research 16 686 (1993)			
Schluter et al. "Pulmonary Administration Type 1 Diabetics" Abstract #298, Diabetes,		Schluter et al. "Pulmonary Administration Type 1 Diabetics" Abstract #298, Diabetes, 33 (Supplement): 75A (1984)		
X	-SA-	Selam et al. "Devices for Insulin Administration" Diabetes Care 13:955-979 (1990)		
X	AB	The Diabetes Control and Complications Trial Research Group "The Effect of Intensive Treatment of Diabetes on the DevelopmentComplications in Insulin-Dependent Diabetes" N. Engl. J. Med. 329:977-986 (1993)		
M	EC	Timsina et al. "Drug Delivery to the Respiratory Tract Using Dry Powder Inahlers" Int. J. Pharmaceutics 101:1-13 (1994)		
X	501	Togitou et al. "Targeted Enteral Delivery of Insulin to Rats" Int. J. Pharm. 30(2-3):95-100		
	- Ma	Wang et al. Parenteral Science and Technology, 42(2S):S4-S26 (1988)		
	EF	Wearly "Recent Progress in Protein and Peptide Delivery by Noninvasive Routes" Critical Rev. Therapeut. Drug Carrier Systems 8:331-394 (1991)		
A	EG	Wetterlin "Turbuhaler: A New Powder Inhaler for Administration of Drugs to the Airways" Pharmaceutical Research 5:506-508 (1988).		
Examiner S	Examiner Signature Date Considered 7 - () 6			

Xavid 1	whan	2-	(-0b)
EXAMINER: Initials citation considered. Draw lin	e through citation if no	t in conformance and not considered	t. Include copy of this form with
next communication to applicant.			•
		0.1	" D'

	Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attomey's Docket No. 06275-004003	Application No.
	Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Bäckström et al.	
			Filing Date	Group Art Unit
	(37 CFR §1.98(b))			

(Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner			
Mitial_	Desig. ID	Document	
Sko	ЕН	Wigley et al. "Insulin Across Respiratory Mucosae by Aerosol Delivery" Diabetes 20:552-556 (1971)	
	EI	Yamamoto et al. "Absorption Enhancement of Intrapulmonary Administered Insulin by Various Absorption" J. Pharm. Pharmacol 46:14-18 (1994)	
EJ Yoshida et al. "Absorption of Insulin Delivered to Rabbit Trachea Using Aerosol Dosage Form J. Pharma. Sci. 68:670-671 (1979)			
	EK	Zingg et al. "Transphatic Absorption and Biliary Excretion of Insulin" Can. J. Physiol. Pharmacol. 65:1982-1987 (1987)	
X	_EL	Zinman 'Medical Intelligence' The Physiologic Replacement of Insulin" N. Engl. J. Med. 321:363-370 (1989)	

Savil Lakton

2-1-06

Examiner Signature

Date Considered